Astria shareholders approve merger with BioCryst

Astria Therapeutics held a special stockholder meeting where investors approved its planned merger with BioCryst Pharmaceuticals.

Rhea-AI Filing Summary

Astria Therapeutics held a special stockholder meeting where investors approved its planned merger with BioCryst Pharmaceuticals. Out of 57,084,838 shares outstanding as of the record date, 35,757,073 shares were present or represented, equal to about 62.64% of the voting power, meaning a quorum was achieved.

Stockholders adopted the Agreement and Plan of Merger with BioCryst, satisfying the requirement for approval by at least a majority of Astria’s outstanding common shares. The merger proposal received 35,673,135 votes for, 12,977 against and 70,961 abstentions. Investors also approved, on a non-binding advisory basis, the merger-related compensation for Astria’s named executive officers, with 33,236,762 votes for, 2,035,104 against and 485,206 abstentions. Because the merger was approved, a backup proposal to adjourn the meeting was not needed. Astria issued a press release announcing the merger vote results.

Insights

M&A and corporate governance analyst

Astria shareholders formally approve BioCryst merger and executive pay.

The key development is stockholder adoption of the merger agreement between Astria Therapeutics and BioCryst Pharmaceuticals. Approval required support from at least a majority of Astria’s outstanding common shares, and the merger proposal cleared that bar with 35,673,135 votes in favor versus 12,977 against and 70,961 abstentions. Quorum was comfortably met, with 35,757,073 shares present or represented, about 62.64% of voting power as of the record date.

Shareholders also gave advisory approval to the merger-related compensation packages for named executive officers, as disclosed in the Golden Parachute Compensation table in the proxy statement. That proposal received 33,236,762 votes for, 2,035,104 against and 485,206 abstentions, indicating broad but not unanimous support. Because the merger proposal passed, the contingency adjournment proposal was moot and not voted.

With these votes completed, the main stockholder approvals tied to the merger have been obtained. The company also issued a press release on January 21, 2026 announcing the approval of the merger proposal, signaling a move into subsequent closing and regulatory steps as defined in the merger agreement.

8-K Event Classification

3 items: 5.07, 8.01, 9.01

3 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Astria Therapeutics (ATXS) stockholders approve at the special meeting?

Stockholders approved the Agreement and Plan of Merger between Astria Therapeutics and BioCryst Pharmaceuticals. This adoption of the merger proposal met the requirement for approval by holders of not less than a majority of Astria’s outstanding common stock.

How many Astria Therapeutics (ATXS) shares voted on the merger proposal?

The merger proposal received 35,673,135 votes for, 12,977 votes against and 70,961 abstentions. Overall, 35,757,073 shares were present in person or by proxy, representing about 62.64% of the voting power eligible to vote at the meeting.

What was the record date and outstanding share count for Astria Therapeutics’ special meeting?

The record date for the special meeting was December 9, 2025. As of the close of business on that date, there were 57,084,838 shares of Astria common stock outstanding and entitled to vote.

Did Astria Therapeutics (ATXS) stockholders approve the merger-related executive compensation?

Yes. On a non-binding, advisory basis, stockholders approved the merger-related named executive officer compensation described in the Golden Parachute Compensation table. The vote was 33,236,762 for, 2,035,104 against, with 485,206 abstentions and no broker non-votes.

Was the adjournment proposal voted on at Astria Therapeutics’ special meeting?

No. Because the merger proposal was approved, the proposal to adjourn the special meeting to a later date if there were insufficient votes was rendered moot and was not called for a vote.

Did Astria Therapeutics issue a press release about the merger vote results?

Yes. On January 21, 2026, Astria issued a press release announcing stockholder approval of the merger proposal. The press release is included as Exhibit 99.1 to the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:11 PM Learn about SEC filing dates

false 0001454789 0001454789 2026-01-21 2026-01-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 21, 2026

Astria Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-37467		26-3687168
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

22 Boston Wharf Road 10th Floor
Boston, Massachusetts		02210
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 349-1971

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ATXS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 5.07. Submission of Matters to a Vote of Security Holders.

A special meeting of stockholders of Astria Therapeutics, Inc., a Delaware corporation (the “Company”), was held on January 21, 2026 at 9:00 a.m., Eastern Time at 22 Boston Wharf Road, 10th Floor, Boston, Massachusetts 02210 (the “Special Meeting”). As of the close of business on December 9, 2025, the record date for the Special Meeting (the “Record Date”), 57,084,838 shares of the Company’s common stock, par value $0.001 per share (“Astria Common Stock”), were outstanding and entitled to vote at the Special Meeting. Each record holder of Astria Common Stock was entitled to one vote for each share of Astria Common Stock owned as of the Record Date.

At the Special Meeting, a total of 35,757,073 shares of Astria Common Stock were present in person or represented by proxy, representing approximately 62.64% of the voting power of the shares of Astria Common Stock issued and outstanding and entitled to vote at the Special Meeting, and, therefore, a quorum was present for the Special Meeting. A summary of the voting results for the proposals presented at the Special Meeting, each of which is described in detail in the Company’s definitive proxy statement, dated December 18, 2025, and first mailed to the Company’s stockholders on or about the date thereof (the “Proxy Statement”), is set forth below.

Merger Proposal

As previously announced, on October 14, 2025, the Company entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”) with BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”), and Axel Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of BioCryst. Adoption of the Merger Agreement (the “Merger Proposal”) required the affirmative vote of holders of not less than a majority of the outstanding shares of Astria Common Stock.

At the Special Meeting, the Company’s stockholders voted upon and approved the Merger Proposal. The votes on this proposal were as follows:

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
35,673,135		12,977		70,961		-

Compensation Proposal

At the Special Meeting, the Company’s stockholders also voted upon and approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation as disclosed in the table entitled “Golden Parachute Compensation” and its accompanying footnotes which is included in the section of the Proxy Statement entitled “The Merger—Interests of Astria’s Directors and Executive Officers in the Merger,” as required by Section 14A of the Securities Exchange Act of 1934, as amended, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Compensation Proposal”). Approval of this proposal required the affirmative vote of holders of shares of Astria Common Stock having a majority in voting power of the votes cast by the holders of all of the shares of Astria Common Stock present or represented at the Special Meeting and voting affirmatively or negatively on such matter. The votes on this proposal were as follows:

Votes For		Votes Against		Votes Abstaining(1)		Broker Non-Votes
33,236,762		2,035,104		485,206		-

(1) Abstentions were not considered votes cast affirmatively or negatively and had no effect on the outcome of the vote on the Compensation Proposal.

Adjournment Proposal

Because the Merger Proposal was approved, the proposal to approve one or more adjournments of the Special Meeting to a later date or dates, if there were insufficient votes to adopt the Merger Agreement on the date of the Special Meeting, was rendered moot and was not called for a vote at the Special Meeting. 

Item 8.01. Other Events.

On January 21, 2026, Astria issued a press release announcing the approval of the Merger Proposal.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 21, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASTRIA THERAPEUTICS, INC.
Date: January 21, 2026	By:	/s/ Ben Harshbarger
		Ben Harshbarger
		Chief Legal Officer